Want to see GB:GSK full AI Analyst Report?
GSK Stock Chart & Stats
1919.50 p
17.50 p(0.91%)
At close: 4:00 PM EDT
1919.50 p
17.50 p(0.91%)
Day’s Range― - ―
52-Week Range1,288.60 p - 2,282.00 p
Previous CloseN/A
Volume794.16K
Average Volume (3M)8.54M
Market Cap
£72.83B
Enterprise Value95.13K
Total Cash (Recent Filing)£3.11B
Total Debt (Recent Filing)£18.24B
Price to Earnings (P/E)15.4
Beta1.11
Next Earnings
Oct 28, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield3.67%
Share Statistics
EPS (TTM)1.20
Shares Outstanding4,045,411,100
10 Day Avg. Volume6,837,178
30 Day Avg. Volume8,542,213
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)4.51
Price to Sales (P/S)2.26
P/FCF Ratio12.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£2,135.85Price Target Upside11.27% Upside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)1.78
Revenue Forecast (FY)£33.87B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityHigh gross and operating margins indicate valuable branded medicines and vaccines, pricing power, and operating scale. These characteristics can support resilient earnings and fund ongoing research, manufacturing investment, and commercial expansion.
Solid Cash GenerationSubstantial operating and free cash flow gives GSK internal funding for R&D, debt service, dividends, and pipeline development. Recent FCF growth strengthens financial flexibility, although conversion quality remains an important monitoring point.
Broad Revenue BaseGSK’s combination of specialty medicines, general medicines, and vaccines across international markets diversifies demand and reduces dependence on one therapy area. A broad commercial base can support durable growth as products and indications evolve.
Bears Say
Meaningful LeverageDebt roughly matching equity leaves GSK more reliant on borrowing than conservatively financed peers. Elevated leverage can constrain investment flexibility and increase refinancing sensitivity if profitability weakens or interest costs remain elevated.
Weakening Cash ConversionLower conversion of accounting profit into free cash flow suggests working capital, tax, capital spending, or other cash demands are absorbing more earnings. If persistent, this could reduce funds available for deleveraging and shareholder returns.
Earnings VolatilityThe decline in net income and uneven historical results indicate that revenue growth is not translating consistently into bottom-line expansion. This may reflect changing product mix, costs, or non-operating effects and reduces confidence in smooth earnings progression.
GlaxoSmithKline News
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1288.60 p and its highest was 2282.00 p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £72.83B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Oct 28, 2026 which is in 70 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jul 28, 2026. The company reported 0.505 p earnings per share for the quarter, beating the consensus estimate of 0.465 p by 0.04 p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of 17 p which represents an annual dividend yield of 3.67%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 0.52.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,045,411,100 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.505 p in its last earnings report, beating expectations of 0.465 p. Following the earnings report the stock price went up 3.468%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£2,135.85 (11.27% Upside)
£2,135.85 (11.27% Upside)
Blogger Sentiment
Neutral
GB:GSK Sentiment 100%
Sector Average 61%
Sector Average 61%
Insider Transactions
Sold Shares
Worth £744.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.62%
12-Months-Change
Fundamentals
Return on Equity
3.67%
Trailing 12-Months
Asset Growth
4.18%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.
GSK Stock 12 Month Forecast
Average Price Target
2,135.85 p
▲(11.27% Upside)
Technical Analysis
AstraZeneca
―
Hikma Pharmaceuticals
―
Smith & Nephew
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Haleon PLC
―










